GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » Median PS Value

DYN (Dyne Therapeutics) Median PS Value : $0.00 (As of Apr. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Dyne Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0. Dyne Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2025-04-01), Dyne Therapeutics's share price is $10.46. Dyne Therapeutics's Median PS Value is $0.00. Therefore, Dyne Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Dyne Therapeutics's Median PS Value or its related term are showing as below:

DYN's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Dyne Therapeutics Median PS Value Historical Data

The historical data trend for Dyne Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyne Therapeutics Median PS Value Chart

Dyne Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Median PS Value
Get a 7-Day Free Trial - - - - -

Dyne Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dyne Therapeutics's Median PS Value

For the Biotechnology subindustry, Dyne Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyne Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's Price-to-Median-PS-Value falls into.


;
;

Dyne Therapeutics Median PS Value Calculation

Dyne Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Dyne Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dyne Therapeutics  (NAS:DYN) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Dyne Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=10.46/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dyne Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyne Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1560 Trapelo Road, Waltham, MA, USA, 02451
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Executives
Richard William Scalzo officer: See Remarks 25 ALBERTA LANE, HOLLISTON MA 01746
Oxana Beskrovnaya officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Dirk Kersten director, 10 percent owner C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Carlo Incerti director FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Jason P Rhodes director, 10 percent owner C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Susanna Gatti High officer: Chief Operating Officer 75 LORIMER ROAD, BELMONT MA 02141
Wildon Farwell officer: Chief Medical Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Jonathan Mcneill officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Joshua T Brumm director, officer: See Remarks ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Atlas Venture Opportunity Fund I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Romesh Subramanian 10 percent owner, officer: Chief Scientific Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451